We are thrilled to announce that Oleena, is now CE marked! This 12th regulatory clearance paves the way to the future commercialization of our oncology DTx in the Europe to support patients and their care teams in the management of cancer treatments. 👉lnkd.in/dJkUFiK

We are proud to announce our new collaboration with Eisai to co-develop innovative digital therapeutics to support patients with cancer based on Theraxium, our core DTx platform. Learn more about this new collaboration here: voluntis.com/en/news/news-1/…

It has been a very busy month for Voluntis with the announcement of several pieces of good news! Well done and thank you to everyone that contributed to these great achievements and made these new collaborations possible! 🎉 To read the latest news: voluntis.com/en/news

Voluntis is committed to the fight against male cancers and diseases by participating in the #Movember Challenge to raise awareness. Let's make sure that our friends, brothers, husbands, sons and fathers are aware to get screened.

Voluntis extends its long-standing partnership with @Microsoft to meet worldwide demand on Digital Therapeutics. We're delighted to announce that we upgraded our secure cloud infrastructure with Azure! To learn more, please read the press release: lnkd.in/d-7gVH8

We’re delighted to announce our new strategic partnership with @Redox the leading interoperability platform for healthcare data exchange. To learn more, read the press release : bit.ly/3kHItLe

Our SVP Global Strategic Alliances, Damien McKeon, will be speaking tomorrow at the virtual event #DTx London during an interactive roundtable on the theme: “How to Commercialise Across Europe and is Pharma the key?”. To watch the event, get registered at dtxlondon.com/register/

We are delighted to start collaborate with @BioconBiologics India Limited, a fully integrated ‘pure play’ biosimilars company, to develop and distribute globally innovative digital therapeutics supporting people with diabetes on biologics therapy. #DTx bit.ly/2COcx6N

Voluntis ensures continuity during COVID-19 crisis. Our teams are working from home and remain 100% committed to maintaining excellent quality of service as we continue to create and operate innovative digital therapeutics and telemonitoring solutions.#staysafe #StayHome #COVID19

Great read on the growth drivers of digital healthcare in 2020! #digitalhealth #dtx #digitaltherapeutics

Happy Holidays! We hope you have a joy-filled holiday season and Happy New Year from all of us at Voluntis.

Congrats to our VP of Medical Affairs, Ellie Strock on receiving @theNCI Director's Award of Merit at the NIH. Well deserved!

#HLTH2019 attendees: Don't miss today's panel discussion at 12:30pm with Voluntis CEO, @PierreLeurent and other industry leaders as they explore Reimbursement Challenges and the Potential for Digital Overload with Emerging Digital Therapeutics.#digitaltherapeutics #digitalhealth

Great read on the potential digital therapeutics have to make chronic disease treatments more accessible and affordable for patients. #DTx #DigitalTherapeutics #DigitalHealth #Oncology #SymptomManagement #Innovation #Oleena

Looking forward to the #ACCCNOC in Orlando next week...We hope to see you there!

Our team is thrilled for the @aafp Annual Conference in Philadelphia this week! Visit us at Booth 412 to learn about @InsuliaT2D, our digital therapeutic supporting basal insulin self-titration for people with type 2 diabetes. #type2diabetes #familyphysicians #DigitalHealth

Thanks to Greg Licholai for the spotlight on Oleena™ in @Forbes! #digitaltherapeutics #DTx #digitalhealth #oncology #symptommanagement #healthcare #innovation Read the full article: forbes.com/sites/greglichola…

Visit our website to learn more about Oleena™, the first digital therapeutic in oncology. voluntis.com/oleena/ #DigitalTherapeutics #DigitalHealth #Oncology #SelfManagement